Blood
Articles in this Issue
Dxo-1801, a liver-targeted siRNA, attenuates inflammation-driven iron restriction and enhances erythropoiesis in non-human primates
Abstract DXO-1801, a Liver-Targeted siRNA, Attenuates Inflammation-Driven Iron Restriction and Enhances Erythropoiesis in Non-Human Primates...
Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia
Abstract Activation of the stimulator of interferon genes (STING) modulates cellular responses in a cell-context-dependent manner. Intrinsic...
National health systems characteristics and lymphoma outcomes: A global analysis
Abstract Background Lymphomas are a heterogeneous group of neoplasms, many of which are potentially curable. While prognosis has markedly im...
A rare case of gelatinous transformation of the bone marrow secondary to untreated hypothyroidism and congestive heart failure
Abstract Abstract Gelatinous transformation of bone marrow (GTBM) is a rare and underdiagnosed condition, with an incide...
Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States
Abstract Introduction: Isocitrate dehydrogenase (IDH) mutations are observed in ~20% of patients with acute myeloid leukemia (AML). In the U...
Synergistic effects of MALT1 inhibitor and selinexor on Acute Myeloid Leukemia cells and the underlying mechanisms
Abstract Background: Current treatment of acute myeloid leukemia (AML) is primarily based on combination chemotherapy, which has certain lim...
A prospective clinical study on the combination of anti-PD1 monoclonal antibody with lenalidomide and azacitidine for the treatment of relapsed/refractory peripheral T-cell lymphoma
Abstract To explore the efficacy and safety of the anti-PD1 monoclonal antibody combined with lenalidomide and azacitidine regimen in the tr...
Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity
Abstract Background: DLBCL is most frequently diagnosed in White males and least commonly in Black females (Wang SS Semin Hematol. 2023;60:2...
Hodgkin lymphoma in a patient with Hemophilia A on emicizumab prophylaxis: A case report
Abstract Background: Historically, persons with hemophilia (PWH) have an increased incidence in cancers, primarily because of the high incid...
Heightened susceptibility of sickle cell trait mice to chlorine-induced multiorgan injury and the protective role of haptoglobin
Abstract Background: Sickle cell trait (SCT), found in 1 in 13 African Americans, is a carrier state of sickle cell disease marked by hetero...
AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia
Abstract Introduction Venetoclax combined with hypomethylating agents (Ven-HMA) has become a standard of care for older...
Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1
Abstract Introduction: The JAK inhibitor ruxolitinib is the first approved drug for the treatment of myelofibrosis (MF), with spleen volume...
Dynamic changes in myeloid derived suppressor cells subsets in pediatric B cell acute lymphoblastic leukemia : Correlation with measurable residual disease status.
Abstract Background:Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that are immunosuppres...
High-dose methotrexate consolidation prior to autologous HSCT in b-ALL: A decade-long retrospective analysis of survival and toxicity outcomes
Abstract Objective To evaluate the impact of high-dose methotrexate (HD-MTX) consolidation on survival outcomes and relapse risk in patients...
Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission
Abstract Background The eradication of measurable residual disease (MRD) is essential for sustaining long-term remission in patients (pts) wi...
Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment
Abstract Background: Despite a recent emphasis on developing regimens for patients (pts) with acute myeloid leukemia (AML) who are unfit for...
Dissection of non-genetic resistance mechanisms by lineage tracing and single cell multiomics reveals drug-specific persister programs in Acute Myeloid Leukemia
Abstract Despite the remarkable success of targeted therapy, the emergence of acquired resistance remains a major obstacle to cure acute mye...
Comparative efficacy and safety of FcRn inhibitors versus placebo in adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials
Abstract Background: Immune thrombocytopenia (ITP) in adults is an autoimmune condition characterized by low platelet counts and an increase...
Targeting BRD4 to reshape the inflammatory microenvironment of senescent bone marrow mesenchymal stem cells for improved hematopoietic stem cell transplantation reconstitution
Abstract Aims Chemotherapy-induced senescence of bone marrow mesenchymal stem cells (BMSCs) and concomitant hypersecreti...
Spatiotemporal and genetic tracking of long-term persisting CAR-T cells following ciltacabtagene autoleucel treatment for multiple myeloma reveals molecular insights into late-onset toxicities
Abstract Introduction Ciltacabtagene autoleucel (cilta-cel) is an anti-BCMA CAR-T cell therapy which led to >70% complete response (C...
BAFFR-CAR T cells (PMB-CT01) show promising safety and anti-leukemia efficacy in relapsed/refractory B-cell ALL patients after CD19-targeted therapy failure, including CD19-negative disease
Abstract Introduction: Immunotherapies targeting CD19, such as blinatumomab and CAR T cells, have shown remarkable efficacy in relapsed/refr...
Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia
Abstract Introduction: BTK inhibitors and BCL2 antagonists are highly active and well-tolerated in Waldenström macroglobulinemia (WM). We in...
Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure
Abstract Introduction To evaluate treatment continuation of gecacitinib in myelofibrosis (MF) patients after ruxolitinib failure, we conduct...
AIM2 inflammasome dependent IL1β and IL-18 signaling is required for initiation of stress erythropoiesis in anemia of inflammation
Abstract Steady-state erythropoiesis continuously produces new erythrocytes, with an estimated rate of 2.5 × 10⁶ erythrocytes per second. Ho...
An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.
Abstract Introduction Allogeneic stem cell transplantation in myelofibrosis carries significant risks, and outcomes rema...